Picard Medical: $67K cash, going-concern warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Picard Medical, Inc. (PMI) reported third-quarter 2026 revenue of $217,000, versus $1.187 million a year earlier, and a net loss of $2.219 million, versus $10.426 million. For the nine months ended September 30, 2026, revenue was $4.321 million versus $3.931 million, while net loss narrowed to $15.495 million from $22.711 million. Operating activities used $7.148 million in cash, and cash and cash equivalents were $67,000 as of September 30, 2026.
Management said operating losses and negative operating cash flows are expected to continue and that substantial doubt exists about PMI’s ability to continue as a going concern for at least 12 months from the financial statements’ issuance; the company says it needs additional financing. In September, PMI issued $1.0 million of convertible notes due September 30, 2027, with a conversion price equal to the greater of $4.00 per share or the market price on the trading day before a conversion notice; conversion also triggers matching pre-funded warrants. NIH/NHLBI awarded SynCardia Systems, LLC an SBIR grant of up to $606,498 for Emperor, a wearable, mechanically actuated total artificial heart, subject to compliance and allowable-cost requirements.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month revenue reached $4.321 million, up from $3.931 million.
- Moderate pointNine-month net loss narrowed to $15.495 million from $22.711 million.
Negative
- Major pointSubstantial doubt exists about continuing as a going concern for at least 12 months.
- Moderate pointThird-quarter revenue was $217,000, versus $1.187 million a year earlier.
Filing Explained
Picard Medical reports that its senior secured note was fully settled by September 30, including 400,430 shares issued for
Key Figures
Key Terms
going concern financial
pre-funded warrant financial
allowable-cost requirements regulatory
fair value option financial
embedded derivatives financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were PMI’s third-quarter 2026 revenue and net loss?
Why did PMI report substantial doubt about continuing as a going concern?
How can PMI’s September 2026 convertible notes convert?
What is the NIH/NHLBI grant to SynCardia for?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
For the transition period from __________ to __________
Commission File Number
PICARD MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| ||
(State or other jurisdiction of |
| (IRS Employer |
(Address of principal executive offices and zip code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
| Trading Symbols |
| Name of Each Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files).
Table of Contents
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
|
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of November 12, 2026, there were
Table of Contents
PICARD MEDICAL, INC.
TABLE OF CONTENTS
|
|
Page |
PART I. FINANCIAL INFORMATION |
|
|
|
|
|
Item 1. |
Financial Statements |
1 |
|
Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 |
1 |
|
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and 2025 |
2 |
|
Unaudited Condensed Consolidated Statements of Changes in Temporary Equity and Stockholders’ Equity for the nine months ended September 30, 2026 and 2025 |
3 |
|
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 |
5 |
|
Notes to Condensed Consolidated Financial Statements (Unaudited) |
6 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
34 |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
42 |
Item 4. |
Controls and Procedures |
42 |
|
|
|
PART II. OTHER INFORMATION |
|
|
|
|
|
Item 1. |
Legal Proceedings |
43 |
Item 1A. |
Risk Factors |
44 |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities |
44 |
Item 3. |
Defaults Upon Senior Securities |
44 |
Item 4. |
Mine Safety Disclosures |
44 |
Item 5. |
Other Information |
44 |
Item 6. |
Exhibits |
45 |
i
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (the “Form 10-Q”) includes statements that are, or may be deemed to be, “forward-looking statements” within the meaning of the U.S. federal securities laws, are statements of future expectations and other forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “opportunity,” “plan,” “potential,” “predict,” “projected,” “should,” “strategy,” “suggests,” “targets,” “will,” “will be” or “would” or similar expressions or the negatives thereof, or other variations thereof, or comparable terminology, or by discussions of strategy, plans or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Form 10-Q and include statements regarding the intentions, beliefs or current expectations of our management teams concerning, among other things, their respective results of operations, financial condition, liquidity, prospects, growth, strategies, and the industry in which they operate.
You are cautioned that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and our actual financial condition, results of operations and cash flows. The development of the industry in which we operate may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this Form 10-Q.
These statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those anticipated by such statements. You should not place undue reliance on these forward-looking statements in deciding whether to invest in our securities. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Factors that could cause such differences in actual results include:
|
● |
Loss of, reduced purchases by, or delayed payments from any of our customers, which are concentrated among a limited number of heart transplant centers, hospitals, surgeons, and their distributors; |
|
● |
Our concentration risk due to reliance on a limited number of products, and the material impact that any disruption in production, quality, regulator status, safety, or market acceptance of these products could have on our business; |
|
● |
Manufacturing of our products is complex, highly manual, and concentrated, which exposes us to risks related to workforce constraints, training timelines, equipment failures, natural disasters, or noncompliance with U.S. Food and Drug Administration ("FDA") regulation; |
|
● |
Our reliance on single- or limited-source suppliers for many critical components, including valves and drive parts, and lack of secondary sources, which could cause shortages and/or require new regulatory clearances or approvals; |
|
● |
Changes in regulatory policy, including new requirements, could lead to delays or denials for new research, expansions, or product upgrades; |
|
● |
Delays or failure to obtain certification under EU Medical Devices Regulation would limit or prevent our growth in European markets; |
|
● |
Clinical studies necessary for approvals, expansions, and updates are costly, lengthy, and uncertain; difficulties with site qualification, enrollment, protocol adherence, adverse events or inconclusive results may prevent or delay approvals; |
|
● |
Device malfunctions or quality issues could lead to field actions, corrections, recalls, investigations, enforcement, reputational harm, and substantial costs, which we may be unable to remediate promptly or effectively; |
|
● |
We could face significant penalties, sanctions, litigation exposure, and reputational damage if our products are misused; |
|
● |
Physician adoption requires education, clinical evidence, and perceived advantages over alternatives; reluctance to adopt total artificial heart therapy may limit demand and financial support; |
ii
Table of Contents
|
● |
Competitive products that are more effective, convenient, or less costly from larger companies with greater resources and relationships could reduce demand for our products; |
|
● |
Profit margin improvement depends on successful product enhancements, and delays or setbacks could constrain profitability even if revenues grow; |
|
● |
Insurance coverage and reimbursements are uncertain and vary by payer and country; insufficient coverage would adversely affect utilization and revenues; |
|
● |
Our industry is heavily regulated and subjects us to evolving and complex healthcare, privacy, and other laws, in addition to the compliance and obligations of being a public company, and can result in civil, criminal, and administrative penalties or business restrictions; |
|
● |
International expansion exposes us to risks including political and economic instability, sanctions, tariffs, export controls, currency fluctuations, local regulatory requirements, limited recourse to protect intellectual property, and challenges overseeing distributors; |
|
● |
Significant product-liability risk is inherent in life-sustaining implantable medical devices, and our insurance coverage may be insufficient or unavailable on acceptable terms, and adverse claims could materially impact our financial condition; |
|
● |
Our reliance on information technology systems and third-party service exposes us to cybersecurity risks, which could disrupt operations, compromise sensitive data, trigger regulatory scrutiny, and lead to significant costs; |
|
● |
Many aspects of our technology are no longer protected by patents and rely on trade secrets and contractual protections, which may be breached or independently developed by others; |
|
● |
Intellectual property disputes could be costly, divert management attention, require licenses or redesigns, or restrict our ability to market products; |
|
● |
Acquisitions, if pursued, involve integration, operational, and financial risks and may not achieve anticipated benefits, which could dilute stockholders, increase leverage, or require significant management attention and resources; |
|
● |
Exposure to credit risk from hospital and distributor receivables, particularly in certain international markets, can increase bad-debt expense and reduce cash collections; |
|
● |
Tax laws could limit our net operating loss carryforwards and increase our cash tax liabilities in future profitable periods; |
|
● |
Significant volatility in our financial results as a result of the Company's election to account for its Senior Secured Note (as defined below) at fair value, as well as the classification of associated warrants as liabilities; |
|
● |
As a newly public company, emerging growth company, and smaller reporting company, we face increased costs to establish effective internal controls and comply with evolving disclosure and governance requirements, which may result in our inability to maintain the Company's NYSE American listing. Furthermore, compliance failures could harm our reputation and stock price; |
|
● |
There can be no assurance that we will be able to comply with the continued listing standards of the NYSE; |
|
● |
The market price of our common stock may be volatile, an active trading market may not develop or be sustained, and/or future equity or debt financings, conversions, or other securities issuances could cause substantial dilution and further volatility; |
|
● |
Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements; |
|
● |
We have been, and may in the future be, subject to securities class action or derivative litigation; and |
|
● |
Any other risk set forth in Part I, Item 1A. Risk Factors of our Form 10-K, filed with the SEC on March 30, 2026. |
We undertake no obligations to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events, other than as required by law.
The forward-looking statements are based on plans, estimates and projections as they are currently available to our management, and we undertake no obligation, and do not expect, to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements referred to above and contained elsewhere in this Form 10-Q.
iii
Table of Contents
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS. |
PICARD MEDICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$
|
|
|
|
$
|
|
|
Restricted Cash |
|
|
|
|
|
|
|
|
Accounts receivable - Trade |
|
|
|
|
|
|
|
|
Accounts receivable - Government grant |
|
|
|
|
|
|
|
|
Inventory, net |
|
|
|
|
|
|
|
|
Due from related parties |
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
|
|
|
|
|
|
Total current assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
|
|
|
|
|
|
Finance lease right-of-use assets, net |
|
|
|
|
|
|
|
|
Operating lease right-of-use assets, net |
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
|
|
|
Total assets |
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities, Temporary Equity, and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$
|
|
|
|
$
|
|
|
Current portion of finance lease liability |
|
|
|
|
|
|
|
|
Current portion of operating lease liability |
|
|
|
|
|
|
|
|
Loans from related parties |
|
|
|
|
|
|
|
|
Senior secured note |
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
| ||
Warrant liability |
|
|
|
|
|
|
|
|
Accrued interest |
|
|
|
|
|
|
|
|
Other accrued liabilities |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance lease liability, net of current portion |
|
|
|
|
|
|
|
|
Operating lease liability, net of current portion |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Temporary equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 30,000,000 shares authorized; 0 Series A-1 issued and outstanding as of September 30, 2026 and December 31, 2025; liquidation value $0 as of September 30, 2026 and December 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value; 300,000,000 shares authorized; 2,458,574 and 1,474,024 shares issued and outstanding as of September 30, 2026 and December 31, 2025 |
|
|
|
|
|
|
|
|
Additional paid-in capital |
|
|
|
|
|
|
|
|
Accumulated other comprehensive income |
|
|
|
|
|
|
|
|
Accumulated deficit |
|
|
( |
)
|
|
|
( |
)
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
Total liabilities, temporary equity, and stockholders’ equity |
|
$
|
|
|
|
$
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
Table of Contents
PICARD MEDICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
|
|
Three Months ended |
|
|
Nine Months ended |
|
||||||||||
|
|
September 30, |
|
|
September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenues, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Rentals |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Rentals |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total cost of revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss) |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Derivative loss |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Change in fair value of Senior secured note and Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss on settlement of debt |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
||
Loss on warrant exchange |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Other income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total other income (expenses), net |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income taxes |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Undeclared Series A-1 preferred dividends |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share—basic and diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding—basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Foreign currency translation adjustments, net of tax |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
Comprehensive loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
Table of Contents
PICARD MEDICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY
AND STOCKHOLDERS’ EQUITY
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated |
|
|
|
|
| |
|
| Series A-1 |
|
|
|
|
|
|
|
|
|
| Additional |
|
|
|
|
|
| Other |
|
|
|
|
| |||||||
|
| Preferred Stock |
|
| Common Stock |
|
| Paid-In |
|
| Accumulated |
|
| Comprehensive |
|
|
|
|
| |||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Income |
|
| Total |
| ||||||||
Balances as of December 31, 2025 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issued to settle debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Translation adjustment |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances as of March 31, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ | ( | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issuance - May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issued with convertible note |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Extinguishment of Warrant Liability |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issued to settle debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Translation adjustment |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances as of June 30, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issued to settle debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issued with convertible note |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Translation adjustment |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances as of September 30, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||||
3
Table of Contents
PICARD MEDICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY
AND STOCKHOLDERS’ EQUITY - (cont.)
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
Series A-1 |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Other |
|
|
|
|
|
|||||||
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Comprehensive |
|
|
|
|
|
|||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Income |
|
|
Total |
|
||||||||
Balances as of December 31, 2024 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ | ( |
) |
|
$ |
|
|
$ | ( |
) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issuance |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Translation adjustment |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances as of March 31, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ | ( |
) |
|
$ |
|
|
$ | ( |
) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issuance |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Translation adjustment |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances as of June 30, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ | ( |
) |
|
$ |
|
|
$ | ( |
) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issuance - IPO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issuance-Pre-IPO Subscriptions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock cancellation |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock issuance for conversion of Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock conversion to Common Stock |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Translation adjustment |
|
|
- |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances as of September 30, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ | ( |
) |
|
$ |
|
|
$ |
|
|||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
Table of Contents
PICARD MEDICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
| | Nine Months ended September 30, | | |||||
| | 2026 | | | 2025 | | ||
Cash flows from operating activities: | | | | | | | | |
Net loss | | $ | ( | ) | | $ | ( | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
Depreciation and amortization | | | | | | | ||
Amortization of right of use asset | | | | | | | ||
Amortization of discount on debt issued | | | | | | | ||
Derivative loss | | | | | | | ||
Changes in fair value of senior secured note and warrant liability | | | ( | ) | | | | |
Provision for excess and obsolete inventory | | | | | | | ||
Stock-based compensation | | | | | | | ||
Loss on settlement of debt | | | | | | | ||
Loss on warrant exchange | | | | | | | ||
Increase in government grant receivable | | | ( | ) | | | | |
Changes in operating assets and liabilities: | | | | | | | | |
Accounts receivable | | | | | | ( | ) | |
Inventory | | | | | | | ||
Prepaid expenses and other assets | | | | | | ( | ) | |
Accounts payable | | | | | | ( | ) | |
Accrued expenses and other liabilities | | | ( | ) | | | | |
Operating lease obligation | | | ( | ) | | | ( | ) |
Net cash used in operating activities | | | ( | ) | | | ( | ) |
| | | | | | | | |
Cash flows from investing activities: | | | | | | | | |
Purchase of plant, property and equipment | | | ( | ) | | | | |
Net cash used in investing activities | | | ( | ) | | | | |
| | | | | | | | |
Cash flows from financing activities: | | | | | | | | |
Proceeds from loans from related parties | | | | | | | ||
Proceeds from issuance of short term notes payable | | | | | | | ||
Repayments of short term notes to third party | | | ( | ) | | | | |
Repayments of loans from related parties | | | ( | ) | | | ( | ) |
Issuance of convertible notes | | | | | | | ||
Stock option exercise | | | | | | | ||
Repayments of senior secured note payable | | | ( | ) | | | | |
Repayments of convertible notes | | | ( | ) | | | ( | ) |
Proceeds from issuance of common stock and warrants | | | | | | | ||
Proceeds from subscription of Common Stock | | | | | | | ||
Proceeds from Common Stock issuance | | | | | | | ||
Repayment of finance lease obligations | | | ( | ) | | | ( | ) |
Net cash provided by (used in) financing activities | | | ( | ) | | | | |
| | | | | | | | |
Effect of exchange rate changes on cash and cash equivalents | | | | | | ( | ) | |
| | | | | | | | |
Net increase (decrease) in cash, cash equivalents, and restricted cash | | | ( | ) | | | | |
Cash, cash equivalents, and restricted cash at beginning of the period | | | | | | | ||
Cash, cash equivalents, and restricted cash at end of the period | | $ | | | $ | | ||
| | | | | | | | |
Supplemental disclosure of cash flow information: | | | | | | | | |
Cash paid for income taxes | | $ | | | $ | | ||
Cash paid for interest | | $ | | | $ | | ||
| | | | | | | | |
Non-cash financing activities: | | | | | | | | |
Issuance of shares for settlement of debt | | $ | | | $ | | ||
Settlement of debt | | $ | | | $ | | ||
Derivative liability recognized on issuance of convertible notes | | $ | | | $ | | ||
Repayment of related party loan through settlement of related party receivable | | $ | | | $ | | ||
Extinguishment of warrants | | $ | | | $ | | ||
Preferred stock conversion to common stock | | $ | | | $ | | ||
Conversion of convertible note and accrued interest to common stock | | $ | | | $ | | ||
Derecognition of derivative liability upon conversion of the convertible notes | | $ | | | $ | | ||
Conversion of note payable to common stock | | $ | | | $ | | ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
Table of Contents
PICARD MEDICAL, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. | DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION AND MANAGEMENT’S PLAN |
Description of Business
Picard Systems, Inc. was incorporated in the state of Delaware on April 8, 2021, for the purpose of investing in and acquiring medical device companies, including SynCardia Systems, LLC (“SynCardia”) and its fully consolidated subsidiaries SynCardia Systems Australia Pty Ltd. ("SynCardia Australia") and SynCardia Systems Europe, GmbH (“SynCardia GmbH”). On September 27, 2021, Picard Systems, Inc. acquired all of the authorized and outstanding membership units of SynCardia and it changed its name to Picard Medical, Inc. (“PMI”, or collectively, the “Company”).
The Company is engaged in the business of designing, manufacturing, production, supply, marketing, and sale of medical device products, including the SynCardia total artificial heart for patients (“SynCardia TAH”). The SynCardia TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. SynCardia GmbH was formed to facilitate the sale and distribution of SynCardia’s products throughout Europe. SynCardia Australia was formed as a wholly owned Australian subsidiary to facilitate research and development in Australia.
Basis of Presentation and Consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. These condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2025, and the related notes which provide a more complete discussion of the Company’s accounting policies and certain other information. The condensed consolidated balance sheet as of December 31, 2025, was derived from the Company’s audited financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position as of September 30, 2026, its results of operations, and changes in temporary equity and stockholders’ equity and cash flows for the three and nine months ended September 30, 2026 and 2025. The results of operations for the three and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any other future annual or interim period.
The condensed consolidated financial statements include the financial statements of PMI and its subsidiaries. All intercompany transactions and account balances between PMI and its subsidiaries have been eliminated in consolidation.
On July 21, 2026, PMI filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $
Going Concern, Liquidity and Management’s Plans
The Company has evaluated whether there are any conditions and events considered in the aggregate that raise substantial doubt about its ability to continue as a going concern for at least twelve months from the date of issuance of these financial statements, and the near term thereafter. The Company has incurred operating losses and negative cash flows from operations for the nine months ended September 30, 2026, and SynCardia has a history of operating losses dating back to its inception. The Company expects that operating losses and negative cash flows from operations will continue into the foreseeable future, and the Company will need to raise additional debt and/or equity financing to fund operations until it generates positive cash flows from operations.
6
Table of Contents
1. | DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION AND MANAGEMENT’S PLAN (cont.) |
To date, the Company’s available liquidity and operations have been financed primarily through the issuance of common stock, preferred stock, and debt. For the year ended December 31, 2025, the Company raised $
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. These estimates are based on information available through the date of the issuance of the financial statements and actual results and outcomes could differ from these estimates and assumptions. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:
| ● | Provisions for income taxes and related valuation allowances and tax uncertainties; |
| ● | Recoverability of long-lived assets and their related estimated useful lives; |
| ● | Accruals for estimated liabilities; |
| ● | Valuation of inventory; |
| ● | Valuation of leased assets; |
| ● | Valuation of stock-based compensation; |
| ● | Valuation of senior secured note; and |
| ● | Valuation of warrants. |
7
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
Foreign Currency Translation
The functional currency of the Company’s subsidiaries in Germany and Australia is their respective local currency. Assets and liabilities are translated into U.S. dollars, the reporting currency, at the exchange rate on the balance sheet date. Revenues and expenses are translated into U.S. dollars at the average rates of exchange prevailing during each reporting period. Foreign currency translation adjustments resulting from this process are reported as an element of comprehensive loss, net of income taxes, on the condensed consolidated statements of operations and comprehensive loss. Transactions executed in different currencies are translated at spot rates and resulting foreign exchange transaction gains and losses are charged to income.
Cash and Cash Equivalents
The Company considers all highly liquid debt investments with a remaining maturity of 90 days or less when purchased to be cash and cash equivalents. The Company places its cash in commercial banks. Accounts in the United States are secured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. From time to time, the Company’s total deposits at commercial banks exceed the balances insured. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area.
Restricted Cash
Restricted cash as of December 31, 2025, represents cash set aside by the Company to comply with the minimum liquidity requirement in our senior secured note due 2028 (the “Senior Secured Note”) by and between the Company and High Trail Special Situations LLC (“High Trail”, "Note Holder"). In March 2026, the Company used $
Financial Instruments and Concentrations of Credit and Business Risk
Financial instruments that potentially subject the Company to a concentration of credit risk principally consist of cash, cash equivalents and accounts receivable.
Fair Value of Financial Instruments
Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, accounts receivable, notes receivable, accounts payable, notes payable, derivative liabilities and accrued liabilities. The Company has elected the fair value option for its Senior Secured Note in accordance with ASC 825, “Financial Instruments”. Under this election, the Senior Secured Note is recognized at fair value at issuance and subsequently remeasured at fair value at each reporting date with changes in fair value recognized in earnings.
Fair Value Measurements
Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity.
8
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:
Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;
Level 2 — Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
Level 3 — Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.
Accounts Receivable - Trade and Allowance for Credit Losses
The Company’s accounts receivable represents amounts considered to be collectible that are owed by its customers. Credit is extended based on evaluation of customers’ financial condition and, generally, collateral is not required. An allowance for credit losses is maintained for expected lifetime losses resulting from the inability of customers to pay, evaluated collectively for accounts with similar risk profiles and individually for unique, high-risk accounts. Expected credit losses are estimated by considering historical experience, current conditions, and reasonable forecasts. After exhausting all collection efforts on past due accounts, an account is written off against the allowance for credit losses. Any collections on accounts previously written off are recorded as income in the period of collection. Based on management's assessment of historical loss data, current economic conditions, and forecasts, expected credit losses are immaterial; consequently, no allowance for credit losses has been recorded.
Accounts Receivable - Government Grant
The Company was awarded a Small Business Innovation Research ("SBIR") grant in 2026. The accounts receivable represents the amount of the expected reimbursement to be received under the terms of the SBIR grant.
Inventory, net
Inventory is stated at the lower of cost, determined using the first in, first out basis, or net realizable value. Inventory consists primarily of raw material components used in the manufacturing of SynCardia TAHs and related equipment as well as work-in-process inventory related primarily to SynCardia TAHs. Finished goods consist primarily of SynCardia TAHs and related equipment, located in Tucson, AZ and at medical centers trained and certified in the implantation of the SynCardia TAH and appropriate patient aftercare (“Centers”). Work-in-process and finished goods include the cost of all direct material, labor, and overhead costs. Inventory write-downs are recorded based on excess and obsolete exposures, determined primarily by future demand forecasts. These write-downs are measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. In addition, a liability is recorded for firm, noncancelable, and unconditional purchase commitments with contract manufacturers and suppliers for quantities that exceed forecasts of future demand. As of September 30, 2026, the Company had
Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation. Improvements, renewals, and extraordinary repairs that materially extend the useful life of the asset are capitalized; other repairs and maintenance charges are expensed as incurred.
Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the condensed consolidated balance sheets, and the resulting gain or loss is reflected in operating expenses in the period realized.
9
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
The useful lives of the property and equipment are as follows:
TAH-Driver equipment (years) |
|
| |
Laboratory equipment (years) |
|
| |
Office and computer equipment (years) |
|
| |
Leasehold improvements |
| Shorter of remaining lease term or estimated useful life |
|
Intangible Assets, net
Intangible assets comprise developed technology and trade name. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives of twelve years for developed technology and five years for trade name.
Goodwill
Goodwill is subject to an annual impairment test, or earlier if indicators of potential impairment exist. The annual impairment test is performed as of December 31 of each year. The Company has the option to perform a qualitative assessment by examining relevant events and circumstances which could have a negative impact on goodwill, including macroeconomic conditions, industry and market conditions, cost factors, overall financial performance, and other relevant events specific to the Company. If, after assessing the totality of events or circumstances described above, the Company determines that it is more likely than not that a reporting unit’s fair value is less than its carrying value, the Company will perform a quantitative impairment test. Upon performing the quantitative impairment test, if the fair value of the reporting unit is less than its carrying amount, goodwill is impaired and the excess of the reporting unit’s carrying value over the fair value is recognized as an impairment loss; however, the loss recognized would not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of completing its impairment test, the Company performs either a qualitative or a quantitative analysis on a reporting unit basis. All of the goodwill is expected to be deductible for income tax purposes.
Quantitative impairment tests consider both the income approach and the market approach to estimate a reporting unit’s fair value. The income and market valuation approaches consider a number of factors that include, but are not limited to, prospective financial information, growth rates, residual values, discount rates and comparable multiples from publicly traded companies in the Company’s industry and require it to make certain assumptions and estimates regarding industry economic factors and the future profitability of the business. As of September 30, 2026 and December 31, 2025, the Company has assessed
Impairment of Long-Lived Assets
The Company evaluates long-lived assets, primarily property and equipment, right-of-use lease assets, developed technology and trade name, for impairment on an annual basis, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When the Company determines that it is probable that undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. Assets to be disposed of by sale, if any, are reported at the lower of the carrying amount or fair value less cost to sell. As of September 30, 2026 and December 31, 2025, the Company has assessed
Revenue Recognition
The Company generates revenue from the sale of its SynCardia TAH, rental of Freedom Drivers, and from training and certification services, which are required before the first time a transplant center may purchase a SynCardia TAH. Revenue includes sales and services to Centers located in the United States as well as Centers domiciled in foreign countries.
10
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
The Company recognizes revenue when it transfers control of promised goods or services to its customers, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition, the Company performs the following five steps:
| (i) | identification of the promised goods or services in the contract; |
| (ii) | determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; |
| (iii) | measurement of the transaction price, including the constraint on variable consideration; |
| (iv) | allocation of the transaction price to the performance obligations based on estimated selling prices; and |
| (v) | recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. |
Product Revenues
The Company recognizes revenue when performance obligations identified under the terms of contracts with its customers are satisfied, which generally occurs, for SynCardia TAH kits, upon the transfer of control in accordance with the contractual terms and conditions of the sale. The majority of the Company’s revenue associated with SynCardia TAH kits are recognized at a point in time when the SynCardia TAH kit is shipped to the customer. The Company only offers assurance-type standard warranties that do not represent separate performance obligations. The Company records amounts billed to customers for reimbursement of shipping and handling costs within revenue. Shipping and handling costs associated with outbound freight after control over a SynCardia TAH kit has transferred to a customer are accounted for as fulfillment costs and are included in cost of revenues. Sales taxes and other usage-based taxes are excluded from revenue. The Company gives certain discounts to product distributors based on a contracted amount on the sale of its products. Discounts applied to invoices are not associated with future purchases and solely relate to the product invoiced. As a result, the invoice and transaction price are recorded net of any discounts. The amount of consideration to which the entity will be entitled in exchange for transferring the promised goods or services to a customer is estimated using the expected value method. Product revenue is billed at the point of sale upon shipment and typically collected within 30 days.
Rental Revenues
Rental revenues primarily consist of rental fees charged to customers who rent the Company’s driver. Rental revenue is earned over the period of usage which begins when a patient is discharged from a hospital and is recognized when it becomes likely that we will receive payment. Rental revenue is billed at month end and typically collected within 30 days.
Professional Services Revenues
Professional services revenues primarily consist of training and certification services. The Company’s professional services revenue is recognized when the services are performed. Professional services revenue is billed upon completion of services and typically collected within 30 days.
Contracts with Multiple Performance Obligations
From time to time, the Company has contracts with customers that contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The Company accounts for individual goods and services separately if they are distinct performance obligations, which often requires significant judgment based upon knowledge of the products and/or services, the solution provided and the structure of the sales contract. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis for those performance obligations with stable observable prices. The Company determines the standalone selling prices based on its overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, pricing when certain services are sold on a standalone basis, the products sold, customer demographics, geographic locations, and the volume of services purchased. As of September 30, 2026 and December 31, 2025, there were
11
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
Returns
The Company does not offer rights of return for its products and services in the normal course of business.
Contract Balances
The Company’s contract liabilities, if any, consist of advance payments for systems as well as deferred revenue on service obligations (see Note 5). As of September 30, 2026 and December 31, 2025, there was
Practical Expedients
The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.
Payment Terms
Payment terms vary by customer but typically provide for the customer to pay within 30 days. Therefore, customer payment terms are for 12 months or less and do not include significant financing components. The Company performs credit evaluations of customers and evaluates the need for allowances for potential credit losses based on historical experience, as well as current and expected general economic conditions.
Cost of revenues
Cost of revenues includes product costs, labor, overhead, inbound freight, and other product-related costs including maintenance costs, excess inventory, and obsolescence charges.
Shipping and Handling Fees and Costs
The Company includes shipping and handling fees billed to customers as part of net sales and shipping and handling costs associated with the outbound freight are included in cost of sales.
Government Grant
The Company accounts for nonexchange government grants using ASC 958-605 by analogy under ASC 105. Grant income is recognized when substantive conditions, including allowable-cost or performance barriers, are substantially met and related rights of return or release no longer prevent recognition. Expected future compliance is not sufficient. Cost reimbursements are recognized as qualifying costs are incurred only to the extent those costs satisfy the applicable conditions. Fixed fees are evaluated separately based on their earning conditions. Grant income is reported in Other Income, separate from revenue from contracts with customers, and related expenses are reported in Research and development.
Unconditional earned amounts not yet collected are recorded as Accounts receivable - Government grant. Cash received before conditions are substantially met is recorded as a refundable advance. The Company evaluates compliance, collectability and potential repayment obligations each reporting period.
Research and Development Costs
Included in research and development costs are wages, stock-based compensation and benefits of employees performing research and development, and other operational costs related to the Company’s research and development activities, including facility-related expenses, allocation of corporate costs, and external costs of outside contractors.
12
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss), and foreign currency translation adjustments, net of tax, which are recorded within other comprehensive income (loss).
Income Taxes
The Company calculates its provision for income tax on the basis of the tax laws enacted at the balance sheet date. The Company uses an asset and liability approach for financial accounting and reporting for income taxes that allows recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain. The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. Due to the Company’s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration of potential shares of common stock.
Diluted net loss per share is calculated by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding plus common share equivalents from conversion of dilutive stock options using the treasury method and Series A-1 Preferred Stock (as defined below in Footnote 9) and Convertible Notes (as defined below in Footnote 8) using the as-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive.
Stock-Based Compensation
The Company measures the fair value of all stock-based awards, including stock options, on the grant date and records the fair value of these awards to compensation expense over the service period. The Company has elected to account for forfeitures as they occur. The fair value of stock option awards is estimated using the Black-Scholes valuation model, which considers several variables and assumptions in estimating the fair value of stock-based awards. These assumptions include:
| ● | per share fair value of the underlying common stock; |
| ● | risk-free interest rate; |
| ● | expected term; |
| ● | expected stock price volatility over the expected term; and |
| ● | expected annual dividend yield. |
The Company calculates the expected term using the simplified method, or the arithmetic average of the original contractual term and the average vesting term, for “plain vanilla” stock option awards. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the stock-based award. PMI is a newly public company with limited stock trading history; therefore, it uses the weighted average of the historic volatilities of the stock price of similar publicly traded peer companies, with extra weighting attached to those companies most similar in terms of size, financial leverage, and business activity. The Company utilizes a dividend yield of zero, as it has no history or plan of declaring dividends on its common stock.
13
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
Leases
The Company records operating leases as right-of-use assets and operating lease liabilities in its condensed consolidated balance sheets for all operating leases with terms exceeding one year. Right-of-use assets represent the right to use an underlying asset for the lease term, including extension options considered reasonably certain to be exercised, and operating lease liabilities represent obligations to make lease payments. Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term. To the extent that lease agreements do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the lease commencement date to determine the present value of lease payments. The expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in operating expenses in the Company’s condensed consolidated statement of operations. The Company has elected to not separate lease and non-lease components of its operating leases.
Segment Information
Operating segments are components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker (“CODM”), who is the Company’s chief executive officer, chief accounting officer, and chief operating officer, in deciding how to allocate resources and assess performance. The CODM evaluates financial information on a consolidated and aggregated basis. Accordingly, the Company has determined that it operates in one operating and reportable segment.
The CODM uses gross profit, reported on a consolidated basis and presented on the condensed consolidated statements of operations and comprehensive loss, to assess performance and allocate resources, including investments in manufacturing, sales and clinical support, and research and development. The CODM also reviews revenue by geography. See Note 5-Revenue.
The measure of segment assets is total consolidated assets. Significant segment expenses are cost of product revenue and cost of rental revenue, which consist of Cost of Revenues, above. Segment information is as follows (in thousands):
| | Nine Months Ended September 30, | | | Three Months Ended September 30, | | ||||||||||
| | 2026 | | | 2025 | | | 2026 | | | 2025 | | ||||
Revenue | | | | | | | | | | | | | | | | |
Products | | $ | | | $ | | | $ | | | $ | | ||||
Rentals | | | | | | | | | | | | | ||||
Total revenue | | | | | | | | | | | | | ||||
| | | | | | | | | | | | | | | | |
Significant segment expenses | | | | | | | | | | | | | | | | |
Cost of product revenue | | | | | | | | | | | | | ||||
Cost of rental revenue | | | | | | | | | | | | | ||||
Total cost of revenue | | | | | | | | | | | | | ||||
| | | | | | | | | | | | | | | | |
Segment and consolidated gross profit | | | | | | | | | | | | | | | | |
Gross profit | | | | | | ( | ) | | | | | $ | ( | ) | ||
| | | | | | | | | | | | | | | | |
Reconciliation to consolidated loss before income taxes | | | | | | | | | | | | | | | | |
Less: research and development | | | | | | | | | | | | | ||||
Less: selling, general and administrative | | | | | | | | | | | | | ||||
Other income (expense), net | | | ( | ) | | | ( | ) | | | ( | ) | | | ( | ) |
Loss before income taxes | | $ | ( | ) | | $ | ( | ) | | $ | ( | ) | | $ | ( | ) |
14
Table of Contents
2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
Recent Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which applies to all public business entities. This standard is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted. The Company expects to adopt this standard for the period beginning after December 15, 2026.
The Company has reviewed all newly issued accounting pronouncements and concluded that they either are not applicable to the Company’s operations, or no material effect is expected on its condensed consolidated financial statements as a result of future adoption.
3. | FAIR VALUE OF FINANCIAL INSTRUMENTS |
The following tables present information about the Company’s financial liabilities that are measured at fair value on a recurring basis and the fair value hierarchy of the valuation (in thousands):
|
| September 30, 2026 |
| |||||||||||||
|
|
|
|
|
| Quoted Prices in |
|
|
|
|
|
|
| |||
|
|
|
|
|
| Active Markets |
|
| Significant |
|
| Significant |
| |||
|
|
|
|
|
| for Identical Assets |
|
| Observable Inputs |
|
| Unobservable Inputs |
| |||
Category Class |
| Total |
|
| (Level 1) |
|
| (Level 2) |
|
| (Level 3) |
| ||||
Senior Secured Note (unpaid principal of $0) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Warrant Liability |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
| December 31, 2025 |
| |||||||||||||
|
|
|
|
|
| Quoted Prices in |
|
|
|
|
|
|
| |||
|
|
|
|
|
| Active Markets |
|
| Significant |
|
| Significant |
| |||
|
|
|
|
|
| for Identical Assets |
|
| Observable Inputs |
|
| Unobservable Inputs |
| |||
Category Class |
| Total |
|
| (Level 1) |
|
| (Level 2) |
|
| (Level 3) |
| ||||
Senior Secured Note (unpaid principal of $15,000) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Warrant Liability |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
The fair value of the Senior Secured Note at issuance had been determined using a discounted cash flow model. In July 2026, the Senior Secured Note was fully settled. The fair value of the Warrant (as defined below in Footnote 8) liabilities at issuance and as of September 30, 2026, was measured using a Monte Carlo simulation model.
The significant unobservable inputs that are included in the valuation model of the Senior Secured Note and Warrants Liability at issuance, at the date of the Warrant Exchange, and as of September 30, 2026 were as follows:
|
| Input Range |
| |||||
|
| Senior Secured Note |
|
| Warrant Liability |
| ||
Significant Unobservable Inputs: |
|
|
|
|
|
|
|
|
Discount rate |
|
|
|
|
| - |
| |
Term to expiration (in years) |
|
|
|
|
|
| ||
Calibration discount |
|
|
|
|
| - |
| |
No exercise window (in years) |
|
| - |
|
|
|
| |
Volatility |
|
| - |
|
|
|
| |
Risk-free rate |
|
| - |
|
|
|
| |
15
Table of Contents
3. | FAIR VALUE OF FINANCIAL INSTRUMENTS (cont.) |
The following table provides a rollforward of the aggregate fair values of the Senior Secured Note and Warrant liability for the nine months ended September 30, 2026 (in thousands):
| | Senior Secured Note | | | Warrant Liability | | ||
Balance as of December 31, 2025 | | $ | | | $ | | ||
Change in fair value | | |
| | | ( | ) | |
Cash payments on Notes Payable | | | ( | ) | | | | |
Loss on settlement of debt | | | | | | | ||
Extinguishment of liability due to Warrant Exchange | | | | | | ( | ) | |
Settlement of Notes Payable via common share issuance | | | ( | ) | | | | |
Balance as of September 30, 2026 | | $ | | | $ | | ||
The decrease in the fair value of the Senior Secured Note and Warrant Liability during the nine months ended September 30, 2026, was primarily driven by changes in valuation assumptions, including the Company’s stock price and volatility.
The following table provides a rollforward of the aggregate fair values of the Senior Secured Note and Warrant Liability for the three months ended September 30, 2026 (in thousands):
| | Senior Secured Note | | | Warrant Liability | | ||
Balance as of June 30, 2026 | | $ | | | $ | | ||
Change in fair value | | |
| | | ( | ) | |
Loss on settlement of debt | | | | | | | ||
Settlement of Notes Payable via common share issuance | | | ( | ) | | | | |
Balance as of September 30, 2026 | | $ | | | $ | | ||
During the nine months ended September 30, 2026, the Company made $
These transactions are reflected in the overall change in fair value presented above. The warrant liability is remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations and comprehensive loss.
The Company has certain non-financial assets, primarily intangible assets, and goodwill, which are measured at fair value on a nonrecurring basis and are adjusted to fair value only to the extent that an impairment charge is recognized. The Company estimates the fair value of these assets using primarily unobservable inputs; therefore, these are considered Level 3 fair value measurements.
16
Table of Contents
4. | CERTAIN BALANCE SHEET COMPONENTS |
| (a) | Inventory, Net |
Inventory, net of provisions for potentially excess, obsolete, or impaired goods, consists of the following (in thousands):
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Raw materials |
| $ |
|
| $ |
| ||
Work in process |
|
|
|
|
|
| ||
Finished goods |
|
|
|
|
|
| ||
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Allowance for excess and obsolete inventory |
|
| ( | ) |
|
| ( | ) |
Inventory, net |
| $ |
|
| $ |
| ||
| (b) | Property and Equipment, Net |
Property and equipment, net consists of the following (in thousands):
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Equipment |
| $ |
|
| $ |
| ||
Furniture and fixtures |
|
|
|
|
|
| ||
Leasehold improvements |
|
|
|
|
|
| ||
Total cost |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Less: accumulated depreciation |
|
| ( | ) |
|
| ( | ) |
Property and equipment, net |
| $ |
|
| $ |
| ||
Depreciation expense was $
| (c) | Intangible Assets, Net |
Intangible assets consist of the following (in thousands):
|
| September 30, 2026 |
| |||||||||
|
| Gross Carrying |
|
| Accumulated |
|
| Net Carrying |
| |||
|
| Amount |
|
| Amortization |
|
| Value |
| |||
Developed Technology |
| $ |
|
| $ | ( | ) |
| $ |
| ||
Trade Name |
|
|
|
|
| ( | ) |
|
|
| ||
Total |
| $ |
|
| $ | ( | ) |
| $ |
| ||
|
| December 31, 2025 |
| |||||||||
|
| Gross Carrying |
|
| Accumulated |
|
| Net Carrying |
| |||
|
| Amount |
|
| Amortization |
|
| Value |
| |||
Developed Technology |
| $ |
|
| $ | ( | ) |
| $ |
| ||
Trade Name |
|
|
|
|
| ( | ) |
|
|
| ||
Total |
| $ |
|
| $ | ( | ) |
| $ |
| ||
17
Table of Contents
4. | CERTAIN BALANCE SHEET COMPONENTS (cont.) |
Amortization expense was $
As of September 30, 2026, developed technology and trade name had remaining lives of
|
| September 30, 2026 |
| |
2026 (three months remaining) |
| $ |
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
2030 |
|
|
| |
Thereafter |
|
|
| |
Total |
| $ |
| |
| (d) | Other Accrued Liabilities |
Other accrued liabilities consist of the following (in thousands):
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Accrued compensation |
| $ |
|
| $ |
| ||
Accrued clinical and manufacturing expenses |
|
|
|
|
|
| ||
Accrued professional and consulting services |
|
|
|
|
|
| ||
Other liabilities, current portion |
|
|
|
|
|
| ||
Total other accrued liabilities, current portion |
| $ |
|
| $ |
| ||
Accrued compensation includes sales commissions, payroll, employee paid time off, and employee and executive officer bonuses. Accrued clinical and manufacturing expenses represent royalties payable under a ten-year worldwide licensing agreement related to intellectual property covering the design and production of valves used in the SynCardia TAH and service costs on drivers returned, mostly from customers outside the U.S. The sums due to the vendor are secured by the license agreement, which is expired. Accrued professional and consulting services represent payables related to legal, accounting, and valuation services provided in preparation of the Company’s period end reporting. At the end of 2023, the Company’s management made the decision to terminate its sales and distribution agreement with State of the Art Medical Products, Inc. In connection with the termination of the agreement, the Company agreed to pay a termination penalty of $
5. | REVENUE |
Disaggregation of Revenue
The Company believes that the nature, amount, timing, and uncertainty of its revenue and cash flows and how they are affected by economic factors are most appropriately depicted by (i) geographic region, based on the shipping location of the customer, and (ii) type of product or service provided.
18
Table of Contents
5. | REVENUE (cont.) |
Total revenue based on the disaggregation criteria described above is as follows (dollars in thousands):
|
| Nine Months Ended September 30, |
| |||||||||||||
|
| 2026 |
|
| 2025 |
| ||||||||||
|
| Revenue |
|
| % of revenue |
|
| Revenue |
|
| % of revenue |
| ||||
Revenue by geographic area |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Europe |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Rest of the world |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Total |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue by type |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Rentals |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Total |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Revenue from products includes related services, which represented less than
|
| Three Months Ended September 30, |
| |||||||||||||
|
| 2026 |
|
| 2025 |
| ||||||||||
|
| Revenue |
|
| % of revenue |
|
| Revenue |
|
| % of revenue |
| ||||
Revenue by geographic area |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Europe |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Rest of the world |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Total |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue by type |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Rentals |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Total |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Revenue from products includes related services, which represented less than 10% of product revenue for the three months ended September 30, 2025. In the three months ended September 30, 2026, sales included $
Contract assets. As of September 30, 2026, and December 31, 2025, there were
Remaining Performance Obligations. Remaining Performance Obligations (“RPO”) comprise deferred revenue plus unbilled contract revenue. As of September 30, 2026 and December 31, 2025, there was
19
Table of Contents
5. | REVENUE (cont.) |
Other Income
Government Grant Income—Excluded from Revenue from Contracts with Customers
In August 2026, the NIH/NHLBI awarded SynCardia Systems, LLC a SBIR Grant", Award No. 1R43HL184460-01, of up to $
The award is accounted for as a nonexchange government grant rather than a contract with a customer under ASC 606. Income recognized under the award is included in Other Income and excluded from customer revenue, customer-revenue disaggregation and ASC 606 contract balances. The Company’s government grant accounting policy is described in Note 2-Summary of Significant Accounting Policies. In the three and nine months ended September 30, 2026, there was $
Funding is subject to allowable-cost requirements, required certifications and reports, and continuing compliance. Unobligated carryover requires prior approval, and noncompliance may result in disallowance, withholding, termination or repayment. The award is not an unconditional right to the full authorized funding.
6. | CONCENTRATIONS |
Customers accounting for more than 10% of revenue in any of the periods presented are summarized as follows (in thousands, except percentages):
|
| Nine Months Ended September 30, |
| |||||||||||||
|
| 2026 |
|
| 2025 |
| ||||||||||
Customer A |
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
Customer C |
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
Customer E |
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
Customer J |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
As of September 30, 2026, Customer J accounted for $
As of December 31, 2025, Customer A accounted for $
Concentrations of revenues derived from foreign countries are disclosed in Note 5.
Long-lived assets by geographic areas are as follows (in thousands):
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
United States |
| $ |
|
| $ |
| ||
Foreign, principally in Europe |
|
|
|
|
|
| ||
Property and equipment, net |
| $ |
|
| $ |
| ||
7. | COMMITMENTS AND CONTINGENCIES |
| (a) | Leases |
The Company has one master lease for office and manufacturing facilities which is considered an operating lease. The Company obtained the right of use of real estate located in Tucson, Arizona, in February 2015 under a lease which was subsequently renewed until January 31, 2027, with no option to renew. The lease currently requires monthly payments of approximately $
20
Table of Contents
7. | COMMITMENTS AND CONTINGENCIES (cont.) |
Right-of-use assets acquired under finance and operating leases consist of the following (in thousands):
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Finance leases: |
|
|
|
|
|
|
|
|
Office equipment |
| $ |
|
| $ |
| ||
Finance lease right-of-use assets, net |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Operating Leases: |
|
|
|
|
|
|
|
|
Facilities |
| $ |
|
| $ |
| ||
Operating lease right-of-use assets, net |
| $ |
|
| $ |
| ||
As of September 30, 2026, the Company had three finance leases for office equipment with a weighted average discount rate of
As of September 30, 2026, and December 31, 2025, the weighted average discount rate for the one operating lease was
The following table summarizes the Company’s undiscounted cash payment obligations for its operating and finance lease liabilities with initial terms of more than twelve months as of September 30, 2026 (in thousands):
|
| Operating Leases |
|
| Finance Lease |
| ||
2026 (three months remaining) |
| $ | 103 |
|
| $ | 21 |
|
2027 |
|
|
|
|
|
| ||
Undiscounted total |
|
|
|
|
|
| ||
Less: imputed interest |
|
| ( | ) |
|
| ( | ) |
Present value of future minimum payments |
|
|
|
|
|
| ||
Current portion of lease liability |
|
| ( | ) |
|
| ( | ) |
Lease liability, net of current portion |
| $ |
|
| $ |
| ||
Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Cash paid for amounts included in the measurement of operating lease liabilities totaled $
|
| Nine Months Ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
Operating lease cost |
| $ |
|
| $ |
| ||
Short-term lease cost |
|
|
|
|
|
| ||
Variable lease cost |
|
|
|
|
|
| ||
Total operating lease cost |
| $ |
|
| $ |
| ||
Cash paid under finance leases totaled $
21
Table of Contents
7. | COMMITMENTS AND CONTINGENCIES (cont.) |
| (b) | China Corporation |
In July 2023, the Company granted SynCardia Medical (Beijing), Inc. (“SynCardia Beijing”) exclusive distribution rights of its products in mainland China, Hong Kong, Macau, and Taiwan. Contingent on the Company becoming publicly traded on a stock exchange, it would be committed to contribute approximately $
As of September 30, 2026, the Company had not made the contemplated investment, and SynCardia Beijing continued to operate solely as an independent distributor. In October 2026, the Company notified SynCardia Beijing that it is terminating the distribution and registration services agreements effective December 15, 2026, and no longer intends to make the investment. See Note 15-Subsequent Events. No amounts related to this arrangement have been recognized as of and for the nine months ended September 30, 2026.
| (c) | Indemnifications |
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company currently has directors’ and officers’ insurance.
| (d) | Litigation |
From time to time the Company may be involved in claims arising in connection with its business. Based on information currently available, the Company believes that the amount, or range, of reasonably possible losses in connection with any pending actions against it in excess of established reserves, in the aggregate, not to be material to its consolidated financial condition or cash flows. However, losses may be material to the Company’s operating results for any particular future period, depending on the level of income or loss for such period.
Louie v. Picard Medical, Inc
On February 2, 2026, a putative securities class action captioned Louie v. Picard Medical, Inc., et al., Case No. 5:26-CV-01024, was filed in the United States District Court for the Northern District of California, San Jose Division. The complaint names the Company as a defendant, along with certain of its current and former officers and directors and other third parties, and purports to assert claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The putative class period alleged is from September 2, 2025, through October 31, 2025. The complaint generally alleges, among other things, that defendants made materially false or misleading statements or omissions in connection with the Company’s initial public offering and subsequent public disclosures, and that the Company’s securities were affected by social-media-based promotion activity. The complaint seeks unspecified compensatory damages, attorneys’ fees and costs, and other relief.
On May 15, 2026, the Court appointed Roger Wiegley and Sobhy Abdelhady as Lead Plaintiffs (“Lead Plaintiffs”) and The Rosen Law Firm, P.A. as lead counsel. On July 28, 2026, Lead Plaintiffs and Named Plaintiff Nicholas Boldery filed an amended class action complaint (the “Amended Complaint”). The Amended Complaint drops the claims under Sections 10(b) and 20 (a) of the Exchange Act. It instead asserts claims under Sections 11 and 15 of the Securities Act of 1933, alleging material omissions in the registration statement for the Company’s initial public offering concerning risks related to market structure or stock price manipulation.
22
Table of Contents
7. | COMMITMENTS AND CONTINGENCIES (cont.) |
On September 28, 2026, the Company and the individual officer and director defendants it represents moved to dismiss the Amended Complaint in its entirety, under Federal Rule of Civil Procedure 12(b)(6). The motion argues, among other things, that (i) the Amended Complaint fails to plead any actionable misstatement or omission in the registration statement, including any violation of Items 105 or 303 of Regulation S-K; (ii) any alleged omission was immaterial as a matter of law; (iii) the negative causation defense under Section 11(e) of the Securities Act bars the claims; and (iv) the Section 15 control person claims fail because no primary violation is alleged. The motion is set for hearing on February 9, 2027.
Parmar v. Fang, et al.
On August 24, 2026, a purported Company stockholder filed a verified derivative complaint, nominally on behalf of the Company, in the United States District Court for the Northern District of California, captioned Parmar v. Fang, et al., Case No. 5:26-CV-00832, against certain current and former directors and officers. The complaint asserts federal securities and fiduciary-duty-related claims arising from allegations similar to those in the securities class action and seeks damages and other relief on behalf of the Company. The Company expects to seek a stay pending resolution of the motion to dismiss in the securities class action and cannot currently predict the outcome or reasonably estimate any potential loss.
The Company believes the claims against the Company and its officers and directors are without merit and intends to defend this matter vigorously. Given the early stage of the proceedings, the outcome is inherently uncertain, the Company cannot reasonably estimate a possible loss or range of loss. The Company will continue to evaluate developments in this litigation for each reporting period and record an accrual for loss contingencies when, to the extent, required by applicable accounting standards.
8. | DEBT |
Senior Secured Note
In December 2025, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with High Trail ("Note Holder") pursuant to which PMI agreed to issue and sell the Senior Secured Note and warrants to purchase shares of our common stock (the "HT Warrants"). An initial $
| ● | Monthly partial redemption payments starting on February 1, 2026, of $ |
| ● | A requirement that the Company maintains a minimum liquidity amount of $ |
| ● | A first priority lien on all tangible and intangible assets of the Company until the outstanding total principal is satisfied. |
| ● | A default interest rate of |
| ● | In connection with a fundamental change, as defined in the Securities Purchase Agreement, a repurchase price of |
The Company issued
23
Table of Contents
8. | DEBT (cont.) |
Upon issuance, the Company elected to account for the Senior Secured Note under the fair value option. The primary reason for electing the fair value option is for simplification and cost-benefit considerations of accounting for the Senior Secured Note at fair value in its entirety versus bifurcation of the embedded features. Under the fair value election, debt issuance costs are expensed as incurred, and the debt liability is subsequently valued at fair market value during each reporting period until settlement. The fair value of the Senior Secured Note at issuance and as of December 31, 2025, amounted to $
In May 2026, the Company entered into a Warrant Issuance and Exchange Agreement wherein the existing HT Warrants were surrendered and exchanged for new warrants to purchase
In connection with the May 2026 Offering (see Note 9), certain adjustment provisions in the PA warrants were triggered, resulting in the placement agent owning an aggregate of
Working Capital Notes
In September 2026, the Company entered into two unsecured short-term promissory notes with BioVanta Investment LLC (“BVI Notes”) in principal amounts of $
Convertible Notes
Between May and September 2023, the Company issued $
24
Table of Contents
8. | DEBT (cont.) |
Between April 2024 and May 2025, the Company issued an additional $
In March 2026, the Company entered into unsecured promissory notes with Fannet Technologies, Inc. (“Fannet Note”) and Anchor Investment, LLC (“Anchor Note”) in principal amounts of $
In April 2026, the Company entered into a securities purchase agreement with Quick Capital, LLC (“Quick Capital”), pursuant to which the Company issued a convertible promissory note in the principal face amount of $
In July 2026, the Company issued a convertible promissory note amounting to $
25
Table of Contents
8. | DEBT (cont.) |
In September 2026, the Company issued three (3) separate unsecured convertible promissory notes (collectively, the “Convertible Notes”) to three (3) accredited investors (collectively, the “Holders”) in an aggregate principal amount of $
9. | TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY |
| (a) | Redeemable Convertible Preferred Stock |
In September 2021, the Company amended the Articles of Incorporation (as amended, the "Articles of Incorporation") to allow for the issuance of
| ● | Dividend Provision: The holders of the preferred stock in preference to the holders of common stock are entitled to receive, if and when declared by the board of directors, dividends at the rate of |
| ● | Conversion Rights: All holders of the Company’s preferred stock have a right to convert the outstanding balances of preferred shares at any time following the date of issuance into a number of fully paid shares of common stock, as specified in the Articles of Incorporation. The conversion rate is the original issue price for the relevant shares divided by the conversion price of the relevant shares, subject to anti-dilution adjustments. In the event of a sale of shares in a public offering resulting in gross proceeds of $ |
| ● | Liquidation Preferences: In the event of any liquidation, dissolution, winding-up or sale or merger of the Company, whether voluntarily or involuntarily, each holder of Preferred Stock is entitled to receive, in preference to the holders of common stock, a per-share amount equal to the original issue price, plus all declared but unpaid dividends. As of September 30, 2026, the redemption preference on liquidation would be approximately $ |
26
Table of Contents
9. | TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (cont.) |
| ● | Voting Rights: Each holder of outstanding shares of Preferred Stock is entitled to the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Holders of Preferred Stock vote together with the holders of Common Stock on an as-converted-to-Common-Stock-basis and not as a separate class. |
| (b) | Common Stock |
The Company is authorized to issue
The holders of common stock are entitled to one vote per share at all meetings of stockholders, provided that they may not vote to amend the Certificate of Incorporation relating to the terms of any outstanding series of Preferred Stock if the holders of that series are entitled to vote thereon. The number of authorized shares of common stock may only be changed by the affirmative vote of the holders of a majority of shares outstanding. There are no sinking fund provisions applicable to the common stock.
The Company had shares of common stock reserved for issuance as follows:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Issued Warrants |
|
|
|
|
|
|
|
|
Available for convertible notes |
|
|
|
|
|
| ||
Options issued and outstanding |
|
|
|
|
|
|
|
|
Available for future grants of equity awards |
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
| (c) | Common Stock Issuance |
In March 2025, the Company entered into subscription agreements with certain investors for the sale of
In April 2025, the Company entered into subscription agreements with certain investors for the sale of
In July 2025, Hunniwell exercised the option to convert all of its Series A-1 Preferred Stock to
In July 2025, the Company received $
In February and March 2026, the Company issued a total of
In February, March, and April 2026, a total of
In April, May, and June 2026, the Company issued a total of
27
Table of Contents
9. | TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (cont.) |
In May 2026, the Company completed the May 2026 Offering of
In April 2026, the Company issued a total of
In July 2026, the Company issued a total of
In August 2026, the Company issued a total of
In August 2026, a total of
Reverse Stock Split
On July 21, 2026, PMI filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $
All historical share numbers, per-share amounts, and common stock details have been retroactively adjusted to reflect the reverse split ratio for all periods presented.
10. | SHARE BASED COMPENSATION |
In September 2021, the Company’s board of directors approved the adoption of the 2021 Equity Incentive Plan, under which the Company is authorized to issue incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock awards and performance awards that may be settled in cash, stock, or other property. On October 10, 2025, the Company’s stockholders approved an amendment to the Company’s 2021 Equity Incentive Plan (as amended, the “Plan”) to (i) increase the aggregate number of shares of Common Stock available under the Plan to a total of
The aggregate number of shares of common stock authorized for issuance under the Plan is
28
Table of Contents
10. | SHARE BASED COMPENSATION (cont.) |
A summary of stock option transactions for the nine months ended September 30, 2026, is as follows:
|
| Shares Available |
|
| Number of Options |
|
| Weighted Average |
| |||
|
| For Grant |
|
| Outstanding |
|
| Exercise Price |
| |||
Balance as of December 31, 2025 |
|
|
|
|
|
|
| $ |
| |||
Granted |
|
| ( | ) |
|
|
|
|
|
| ||
Exercised |
|
|
|
|
| ( | ) |
|
|
| ||
Cancelled |
|
|
|
|
| ( | ) |
| $ |
| ||
Balance as of September 30, 2026 |
|
|
|
|
|
|
| $ |
| |||
As of September 30, 2026, there were
As of September 30, 2025, there were
In February 2026, the Company granted
Stock Price |
|
| $ |
|
Expected dividend yield |
|
| % | |
Expected stock price volatility |
|
| % | |
Risk-free interest rate |
|
| 3.66%-4.26 | % |
Expected term (years) |
|
|
|
A summary of stock option transactions is as follows (in thousands):
|
| Nine Months Ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
Cost of revenue |
| $ |
|
| $ |
| ||
Research and development |
|
|
|
|
|
| ||
Selling, general and administrative |
|
|
|
|
|
| ||
Total stock-based compensation |
| $ |
|
| $ |
| ||
As of September 30, 2026 the unrecognized stock-based compensation cost related to outstanding stock options that are expected to vest was $
As of September 30, 2025, the unrecognized stock-based compensation cost related to outstanding stock options that are expected to vest was $
29
Table of Contents
11. | INCOME TAXES |
The primary differences between the federal statutory income tax rate and the Company’s effective tax rate are due to permanent differences such as meals and entertainment expenses that are non-deductible for tax, state income taxes, the net change in valuation allowance, and other non-taxable items.
The tax effects of temporary differences and carryforwards that gave rise to significant portions of the deferred tax assets and liabilities for the nine months ended September 30, 2026 and 2025, were net operating loss carryforwards, accruals and reserves, credits, fixed assets, and other items.
As of December 31, 2025, a full valuation allowance was provided for the tax benefits that may not be realized and is still in effect as of September 30, 2026. Management believes, based on a variety of factors, it is more likely than not that the deferred income tax assets will not be fully realized.
12. | NET LOSS PER SHARE |
Basic and diluted net loss per share is shown in the condensed consolidated statements of operations and comprehensive loss.
No adjustment has been made to the net loss for charges related to the Convertible Notes, Series A-1 Preferred Stock, and Warrants as the effect would be anti-dilutive due to the Company’s net loss. The following outstanding stock options, warrants, and shares issuable upon conversion of the Convertible Notes and the Series A-1 Preferred Stock were not considered in the computation of diluted net loss per share attributable to holders of common stock as they had antidilutive effects:
|
| Nine Months Ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
Shares of common stock issuable upon exercise of common stock options |
|
|
|
|
|
| ||
Shares of common stock issuable upon exercise of issued warrants |
|
|
|
|
|
| ||
Shares of common stock issuable upon conversion of Convertible Notes* |
|
|
|
|
|
| ||
Total common shares excluded from denominator for diluted earnings per share computation |
|
|
|
|
|
| ||
* Convertible notes contained pre-funded warrant feature.
13. | RETIREMENT PLANS |
The Company maintains a 401(k) Plan for the benefit of eligible employees in the United States. The 401(k) Plan includes a cash or deferred arrangement pursuant to Section 401(k) of the Internal Revenue Code sponsored by the Company to provide eligible employees with an opportunity to defer compensation and have such deferred amounts contributed to the 401(k) Plan on a pre-tax basis, subject to certain limitations. The Company, at the discretion of the Board of Directors, may make contributions of cash to match deferrals of compensation by participants in the 401(k) Plan. To date, the Company has made
30
Table of Contents
14. | RELATED PARTY TRANSACTIONS |
Related Party Notes
On various dates in January, March, and June 2025, the Company borrowed an aggregate of $
In July 2025, the Company amended a $
In July 2025, the Company borrowed $
In August 2025, the Company borrowed $
In November 2025, the Company borrowed $
In February 2026, the Company borrowed $
31
Table of Contents
14. | RELATED PARTY TRANSACTIONS (cont.) |
Between July 2026 and September 2026, the FFF-II, an entity affiliated with Dr. Fang, lent the Company an aggregate principal amount of $
The term Collateral in the above loans refers to all assets of the Company, including without limitation all of the Company’s right, title, and interest in assets, whether now owned or hereafter acquired or arising and wherever located.
Stock Based Compensation
In May 2026, the Company granted
15. | SUBSEQUENT EVENTS |
In connection with the issuance of the condensed consolidated financial statements for the nine months ended September 30, 2026, the Company has evaluated subsequent events through November 16, 2026, the date the condensed consolidated financial statements were issued, and identified the following subsequent events requiring disclosure.
Convertible Notes
In October 2026, the Company issued
Warrant Amendment and Exchange Agreement
In October 2026, the Company entered into a Warrant Amendment and Exchange Agreement (the “Exchange Agreement”) with the placement agent holding the
Related Party Loans
In October 2026, the Company entered into unsecured promissory notes with Fang Family Fund, LLC- Series II (“FFF II”), an entity affiliated with one of its executive directors and chief executive officer, an aggregate principal amounts of $
Working Capital Loans
In October 2026, the Company entered into an unsecured short-term loan agreement with an individual lender for the principal amount of $
32
Table of Contents
15. | SUBSEQUENT EVENTS (cont.) |
In October 2026, the Company entered into an unsecured short-term loan agreement with an individual investor, for the principal amount of $
China Corporation
In October 2026, the Company notified SynCardia Beijing of its decision to terminate the Exclusive Distribution Agreement and the related Registration Services Agreement, effective December 15, 2026. In connection with the termination, the Company requested the orderly transfer of registration, technical and other materials relating to the Company’s products and registration activities in China. Accordingly, the Company no longer intends to consummate the previously contemplated investment in SynCardia Beijing. The Company is evaluating the financial effects of the termination and, as of the date of issuance of these condensed consolidated financial statements, such effects cannot be reasonably estimated.
Bylaw Amendment
In October 2026, the Board approved an amendment to the Company’s Amended and Restated Bylaws, effective immediately, reducing the quorum required for meetings of stockholders from a majority of the voting power of the outstanding shares entitled to vote to thirty-three and one-third percent (33 1/3%) of such voting power.
Appointment of CEO
In October 2026, the Board appointed Richard Fang, Ph.D., as Chief Executive Officer of the Company on a permanent, full-time basis. Dr. Fang had served as Interim Chief Executive Officer since June 18, 2026 and continues to serve as Chairman of the Board. The appointment involved no new or amended compensation or employment arrangement.
Freedom Driver Development Agreement
On November 4, 2026, SynCardia Systems, LLC, a subsidiary of the Company, entered into a development and manufacturing agreement with Tianjin Yue’an Medical Technology Co., Ltd. for the Freedom Driver System. The agreement provides for aggregate development payments of $
33
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is a discussion and analysis of our financial condition and results of operations. The following should be read in conjunction with our financial statements and accompanying notes. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected, forecasted, or expected in these forward-looking statements as a result of various factors, including, but not limited to, those discussed below and elsewhere in this Form 10-Q. See “Cautionary Statement Regarding Forward-Looking Statements” in this report, and the risk factors set forth in Part I, Item 1A. Risk Factors in our Form 10-K, filed with the SEC on March 30, 2026.
Overview
PMI functions as a holding company and owns 100% of the membership interests of SynCardia. Business operations are carried out by and through SynCardia, and accordingly most of the information set forth in this Quarterly Report on Form 10-Q relates to the business of SynCardia. SynCardia is a medical technology company that manufactures and sells the only U.S. Food and Drug Administration (“FDA”) and Health Canada approved SynCardia TAH, which fully replaces the function of a failing human heart. To date, more than 2,100 SynCardia TAHs have been implanted in patients across 27 countries, and the SynCardia TAH is an established bridge to heart transplantation for patients with biventricular heart failure, also referred to as end-stage heart failure, in the U.S. and around the globe. We are also pursuing additional research and advancements in medical technology, including the next-generation Emperor Total Artificial Heart (“Emperor TAH”), which is designed to combine the proven SynCardia TAH ventricles with the Company’s next-generation electromechanical Emperor Drive System. The Emperor TAH is being developed as a platform to a fully implantable total artificial heart and eliminate the need for external drivers. The Emperor TAH is subject to additional development and regulatory review.
We continue development of the Emperor TAH program. In July 2026, we publicly presented the integrated architecture of the Emperor TAH platform at the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (“IEEE EMBC 2026”), providing the biomedical engineering community with a detailed view of the platform and its electromechanical drive architecture.
During the third quarter of 2026, preclinical and engineering development of the Emperor platform continued, including motor and control-system development, design optimization and bench testing. Early reliability testing of the Emperor drive system has exceeded 18 million operating cycles to date.
We also continue to pursue development of a next-generation pneumatic driver for the SynCardia TAH, with the objective of reducing costs, improving supply availability and supporting broader adoption of the SynCardia TAH.
The currently approved SynCardia TAH System consists of an implant including: (i) left and right artificial ventricles; (ii) external pneumatic drivers that power the implant; and (iii) drivelines that connect the external driver to the implant. The implantation procedure follows routine surgical techniques used by cardiothoracic surgeons performing heart transplantation. The system provides immediate and complete cardiac output by replacing both ventricles and all four heart valves. The SynCardia TAH is powered by pneumatic drivers available for in-hospital use, the Companion 2 Driver, and for in-home use, the Freedom Driver. These systems generate true pulsatile flow using a redundant pneumatic pump assembly, restoring full hemodynamics and giving patients time to stabilize, recover, and ultimately receive a heart transplant. Patients supported by the SynCardia TAH may be discharged from the hospital using the portable Freedom Driver.
Implantation of the SynCardia TAH is covered by the U.S. Centers for Medicare and Medicaid Services under National Coverage Determination 20.9.1 and is generally reimbursed under Diagnosis Related Group 001, the highest reimbursement category for cardiac procedures. Hospital reimbursement varies based on case complexity and institutional adjustments. Because reimbursement is determined primarily by the procedure rather than the specific device used, hospitals evaluate mechanical circulatory support technologies based on clinical suitability and overall cost effectiveness within the applicable reimbursement framework. We currently have SynCardia TAH inventory available to support near-term customer requirements.
Government Grant
In August 2026, the NIH/NHLBI awarded SynCardia Systems, LLC a SBIR Grant, Award No. 1R43HL184460-01, of up to $606,498 to support development of a wearable, mechanically actuated total artificial heart known as Emperor. The project and budget periods extend from September 1, 2026 through August 31, 2027. The authorized award amount is not the amount of income recognized or cash received.. In the three and nine months ended September 30, 2026, we recognized $0.1 million in Other Income from the SBIR Grant. As of November 12, 2026, we had recognized $0.2 million of grant funds as Other Income.
34
Table of Contents
Loss of Controlled Company Status
Following the May 2026 Offering, Hunniwell no longer controls a majority of the voting power of the outstanding common stock of PMI, causing the Company to cease being a "controlled company" within the meaning of applicable rules of NYSE American. The Company is now subject to compliance with the independence requirements regarding board composition, compensation committee membership, and nominating committee membership. While PMI currently complies with all other corporate governance requirements of the NYSE American Company Guide, it will transition to a majority independent board by May 6, 2027, and expects to achieve full compliance within that deadline.
NYSE Notice
On May 8, 2026, the Company received a notice of noncompliance from NYSE Regulation (the “NYSE Notice”) stating that it was not in compliance with Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) because it reported stockholders’ equity of $3.8 million as of December 31, 2025 and net losses in three of its four most recent fiscal years (the “Stockholders’ Equity Rule”). The Company timely submitted a plan of compliance (the “Compliance Plan”) by the June 7, 2026 deadline. On July 22, 2026, the NYSE American notified the Company that it had accepted the Compliance Plan to regain compliance with Sections 1003(a)(i) and (ii) of the Company Guide, noting previously disclosed stockholders’ equity of $3.8 million as of December 31, 2025 and a stockholders’ deficit of $(1.4) million as of March 31, 2026.
The acceptance allows the Company to continue its listing on the NYSE American, subject to achieving the milestones in the Compliance Plan and quarterly NYSE American review, for a maximum of 18 months from the NYSE Notice, ending November 8, 2027. As of September 30, 2026, the Company reported stockholders’ equity of $1.3 million.
Components of Our Results of Operations
Revenues
We generate revenue from the sale of our SynCardia TAH for patients, rental of Freedom Drivers, and from training and certification services, which are required before the first time a transplant center may deploy a SynCardia TAH. Revenue includes sales and services Centers located in the U.S. as well as Centers domiciled in foreign countries.
Cost of Revenues
Cost of revenues includes product costs, labor, overhead, inbound freight, and other product-related costs including excess inventory and obsolescence charges.
Research and Development
Research and development expenses include wages, stock-based compensation and benefits of employees performing research and development, and other operational costs related to our research and development activities, including facility-related expenses, allocation of corporate expenses, and external costs of outside contractors. While research and development supply expense are isolated by product, personnel are not. Research and development personnel do not work on current product production, therefore labor expense is not isolated by product.
Selling, General and Administrative
Selling, general and administrative expenses consist primarily of personnel-related expenses for executives, human resources, finance, and other general and administrative employees, including salary and stock-based compensation, professional services costs, and allocation of facility and overhead costs.
Our general and administrative expenses will increase in the future in connection with ongoing costs of operating as a public company, including expanding headcount and increased fees for directors and outside advisors. We expect to incur significant costs to comply with corporate governance, internal controls, and similar requirements applicable to public companies. Additionally, we expect to incur increased costs associated with establishing sales, marketing, and revenue growth.
35
Table of Contents
Other Income (Expenses), net
Other income (expenses), net primarily consists of interest expense, changes in fair value of Senior secured note and Warrant liability, and Loss on settlement of debt.
Provision for Income Taxes
We are subject to U.S. federal and state income taxes and foreign taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in deferred tax assets, and liabilities and changes in tax laws. Provision for income taxes primarily relates to state income taxes.
Results of Operations
Comparison of Nine Months Ended September 30, 2026 and 2025
The following table summarizes Picard’s results of operations (in thousands, except percentages) (unaudited):
|
|
Nine Months Ended September 30, |
|
|
Change |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
$ |
|
|
% |
|
||||
Revenues, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
$ |
3,878 |
|
|
$ |
3,859 |
|
|
$ |
19 |
|
|
|
0 |
% |
Rentals |
|
|
443 |
|
|
|
72 |
|
|
|
371 |
|
|
|
515 |
% |
Total revenues |
|
|
4,321 |
|
|
|
3,931 |
|
|
|
390 |
|
|
|
10 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
|
2,157 |
|
|
|
2,999 |
|
|
|
(842 |
) |
|
|
-28 |
% |
Rentals |
|
|
1,178 |
|
|
|
1,547 |
|
|
|
(369 |
) |
|
|
-24 |
% |
Total cost of revenues |
|
|
3,335 |
|
|
|
4,546 |
|
|
|
(1,211 |
) |
|
|
-27 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss) |
|
|
986 |
|
|
|
(615 |
) |
|
|
1,601 |
|
|
|
-260 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
3,590 |
|
|
|
2,502 |
|
|
|
1,088 |
|
|
|
43 |
% |
Selling, general and administrative expenses |
|
|
8,637 |
|
|
|
7,137 |
|
|
|
1,500 |
|
|
|
21 |
% |
Total operating expenses, net |
|
|
12,227 |
|
|
|
9,639 |
|
|
|
2,588 |
|
|
|
27 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(11,241 |
) |
|
|
(10,254 |
) |
|
|
(987 |
) |
|
|
10 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income and expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(109 |
) |
|
|
(5,386 |
) |
|
|
5,277 |
|
|
|
-98 |
% |
Derivative gain (loss) |
|
|
- |
|
|
|
(7,040 |
) |
|
|
7,040 |
|
|
|
-100 |
% |
Change in fair value of Senior secured note and Warrant liability |
|
|
6,410 |
|
|
|
- |
|
|
|
6,410 |
|
|
|
100 |
% |
Loss on settlement of debt |
|
|
(10,162 |
) |
|
|
- |
|
|
|
(10,162 |
) |
|
|
-100 |
% |
Loss on warrant exchange |
|
|
(505 |
) |
|
|
- |
|
|
|
(505 |
) |
|
|
-100 |
% |
Other income |
|
|
119 |
|
|
|
- |
|
|
|
119 |
|
|
|
-100 |
% |
Total other income (expenses), net |
|
|
(4,247 |
) |
|
|
(12,426 |
) |
|
|
8,179 |
|
|
|
-66 |
% |
Loss before income taxes |
|
|
(15,488 |
) |
|
|
(22,680 |
) |
|
|
7,192 |
|
|
|
-32 |
% |
Provision for income tax |
|
|
(7) |
|
|
|
(31 |
) |
|
|
24 |
|
|
|
-77 |
% |
Net loss |
|
$ |
(15,495 |
) |
|
$ |
(22,711 |
) |
|
$ |
7,216 |
|
|
|
-32 |
% |
36
Table of Contents
Revenues
Total revenues increased by $0.4 million, or 10%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. This increase is due to an increase in U.S. rental sales of $0.4 million.
Cost of Revenues
Total cost of revenues decreased by $1.2 million, or 27%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The decrease was primarily driven by improved gross margins on product sales, which more than offset the costs associated with rental sales. As a result, total cost of revenue decreased to 77% of total sales for the nine months ended September 30, 2026, compared with 116% for the corresponding period in 2025. This is due to improved finished goods inventory management between the periods.
Research and Development Expenses
Research and development expenses increased by $1.1 million, or 43%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The increase was primarily attributable to increased activity and phase scheduling in of new product research. We do not track expenses by product candidate. While research and development supply expense are isolated by product, personnel are not. Research and Development personnel do not work on current product production, therefore labor expense is not isolated by product.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $1.5 million, or 21%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The increase was primarily attributable to a $1.1 million increase in stock based compensation expenses, and $0.6 million of allocated labor cost, offset by $0.2 million in professional service fee reduction.
Total Other Income (Expenses)
Total other expenses decreased by $8.2 million, or 66%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The decrease was primarily attributed to (i) the absence in 2026 of the $7.0 million Derivative loss recognized in 2025, (ii) a $5.3 million decrease in Interest expense, (iii) and a $6.4 million gain from Change fair value of the Senior secured note and Warrant liability, (iv) $0.1 million in SBIR grant revenue, and (v) $0.013 million in other income; offset by (i) a $10.2 million Loss on settlement of debt and (ii) a $0.5 million Loss on the warrant exchange.
37
Table of Contents
Comparison of Three Months Ended September 30, 2026 and 2025
The following table summarizes Picard’s results of operations (in thousands, except percentages) (unaudited):
|
|
Three Months Ended September 30, |
|
|
Change |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
$ |
|
|
% |
|
||||
Revenues, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
$ | - |
|
|
$ | 1,115 |
|
|
$ | (1,115 | ) |
|
|
-100 | % |
Rentals |
|
|
217 |
|
|
|
72 |
|
|
|
145 |
|
|
|
201 | % |
Total revenues |
|
|
217 |
|
|
|
1,187 |
|
|
|
(970 | ) |
|
|
-82 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
|
- |
|
|
|
880 |
|
|
|
(880 | ) |
|
|
-100 | % |
Rentals |
|
|
122 |
|
|
|
437 |
|
|
|
(315 | ) |
|
|
-72 | % |
Total cost of revenues |
|
|
122 |
|
|
|
1,317 |
|
|
|
(1,195 | ) |
|
|
-91 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss) |
|
|
95 |
|
|
|
(130 | ) |
|
|
225 |
|
|
|
-173 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
321 |
|
|
|
951 |
|
|
|
(630 | ) |
|
|
-66 | % |
Selling, general and administrative expenses |
|
|
1,875 |
|
|
|
2,406 |
|
|
|
(531 | ) |
|
|
-22 | % |
Total operating expenses |
|
|
2,196 |
|
|
|
3,357 |
|
|
|
(1,161 | ) |
|
|
-35 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(2,101 | ) |
|
|
(3,487 | ) |
|
|
1,386 |
|
|
|
-40 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income and expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(15 | ) |
|
|
(2,404 | ) |
|
|
2,389 |
|
|
|
-99 | % |
Derivative gain (loss) |
|
|
- |
|
|
|
(4,535 | ) |
|
|
4,535 |
|
|
|
-100 | % |
Change in fair value of Senior secured note and Warrant liability |
|
|
669 |
|
|
|
- |
|
|
|
669 |
|
|
|
100 |
% |
Loss on settlement of debt |
|
|
(878 | ) |
|
|
- |
|
|
|
(878 | ) |
|
|
-100 |
% |
Other income |
|
|
106 |
|
|
|
- |
|
|
|
106 |
|
|
|
100 | % |
Total other income (expenses), net |
|
|
(118 | ) |
|
|
(6,939 | ) |
|
|
6,821 |
|
|
|
-98 | % |
Loss before income taxes |
|
|
(2,219 | ) |
|
|
(10,426 | ) |
|
|
8,207 |
|
|
|
-79 | % |
Provision for income tax |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0 | % |
Net loss |
|
$ | (2,219 | ) |
|
$ | (10,426 | ) |
|
$ | 8,207 |
|
|
|
-79 | % |
38
Table of Contents
Revenues
Total revenues decreased by $1.0 million, or 82%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. This decrease was due to a decline in Product sales, offset by a $0.1 million increase in Rental sales. During the three months ended September 30, 2026, we recognized no Product sales revenue, compared to $1.1 million in the prior-year period. Rental revenues increased $0.1 million due to higher utilization of leased equipment.
The absence of Product sales resulted from our hospital customers having no eligible patients scheduled during the period, not from order cancellations, customer losses, or a known adverse trend or uncertainty in underlying demand. Based on preliminary results and confirmed orders as of November 12, 2026, we expect net product sales for the three months ending December 31, 2026, to exceed the $0.9 million we reported for the three months ended December 31, 2025, primarily due to orders received for TAHs. This forward-looking statement is subject to risks and uncertainties, including potential changes in customer delivery schedules, that could cause actual results to differ materially. See Cautionary Note Regarding Forward-Looking Statements and Part II, Item 1A, Risk Factors.
Cost of Revenues
Total cost of revenues decreased by $1.2 million, or 91%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was mainly due to (i) a $0.9 million decrease in improved finished goods inventory management fees as we shift select manufacturing activities in-house, allowing us to utilize existing internal personnel and facilities more efficiently while also onboarding more cost-effective suppliers, and (ii) by a $0.3 million decrease in rental costs. We expect external expenditures to moderately increase in upcoming quarters as supplier transitions are finalized and development timelines resume.
Rental revenue and rental cost are not directly correlated. Rental revenue is earned when a patient is discharged from a hospital with a Freedom Driver and is recognized when it becomes likely that we will receive payment. Rental costs consist mainly of machine maintenance needed to maintain reliability and are incurred on a time schedule that depends on how long the driver is actually used; a single driver may serve multiple patients before maintenance service is required. Because the timing of usage and payment receipt generally does not correlate with the cost of service maintenance. Our total cost of revenue as a percentage of total sales for the three months ended September 30, 2026 and 2025 was 56% and 111%, respectively.
Research and Development Expenses
Research and development expenses decreased by $0.6 million, or 66%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was primarily attributable to decreased activity and phase scheduling in of new product research. We do not track expenses by product candidate. While research and development supply expense are isolated by product, personnel are not. Research and Development personnel do not work on current product production, therefore labor expense is not isolated by product.
Selling, General and Administrative Expenses
Selling, general and administrative expenses decreased by $0.5 million, or 22%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was primarily attributable to $0.5 million reduction in salary and wages.
Total Other Income (Expenses)
Total other expenses decreased by $6.8 million, or 98%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was primarily attributable to (i) the absence in 2026 of the $4.5 million Derivative loss recognized in 2025, (ii) a $2.4 million decrease in Interest expense, and (iii) a $0.7 million gain from Change in fair value of the Senior secured note and Warrant liability, (iv) $0.1 million in SBIR grant revenue; partially offset by (i) a $0.9 million Loss on settlement of debt.
39
Table of Contents
Liquidity and Capital Resources
Funding Requirements and Going Concern
We have incurred operating losses since inception, including net losses of $15.5 million and $22.7 million for the nine months ended September 30, 2026 and 2025, respectively. While we already have FDA-approved products that are generating commercial revenue, the business needs to scale up in order to offset a large, fixed overhead cost from our site in Tucson, Arizona. Moreover, we are also investing heavily in the development of updates and next generation devices; therefore, we expect to continue to incur significant expenses and operating losses for the foreseeable future. Furthermore, we expect to incur additional expenses with operating as a public company.
Until such time as we can sufficiently grow product and rental revenue, we expect to finance our cash needs through a combination of equity and debt financing, or other capital sources, including related parties. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted. The terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we are unable to raise sufficient funds through equity or debt financing, we may be required to delay, limit, curtail or terminate our product development or future growth efforts. Additionally, we may never become profitable, or if we do, may not be able to sustain profitability on a recurring basis.
We have considered that our long-term operations anticipate continuing net losses and the need for potential debt or equity financing. However, there can be no assurances that additional funding or other sources of capital will be available on terms acceptable to us, or at all. If additional capital is not secured when required, we may need to delay or curtail our operations until such funding is received. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected. As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this filing are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to increase sales and raise additional funds and financing. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in Part I, Item 1A. Risk Factors of our Form 10-K filed March 30, 2026.
Sources of Liquidity
To date, we have funded our operations primarily with proceeds from our Series A-1 Preferred Stock, loans from related parties, convertible notes, and sales of common stock or loans from other investors. We completed our Initial Public Offering in September 2025. In December 2025, we entered into a Securities Purchase Agreement under which we issued a $15.0 million Senior Secured Note due 2028, with the right to issue up to an additional $35.0 million in subsequent closings.
In May 2026, we completed the May 2026 Offering of 333,333 shares of common stock (or pre-funded warrants in lieu thereof for certain purchasers), Series A Common Warrants for up to 333,333 shares, and Series B Common Warrants for up to 333,333 shares, at a combined price of $15.0 per share, for gross proceeds of $5.0 million. Net proceeds were $3.1 million after $0.9 million of offering costs and $1.0 million applied in a cashless transaction to settle Senior Secured Note principal. We also used net proceeds to repay in full the Fannet, Anchor, and Quick Capital Notes.
The unpaid principal of the Senior Secured Note decreased from $15.0 million to no principal remaining outstanding as of September 30, 2026, through cash repayments and share settlements.
During 2026, we also obtained approximately $3.6 million of loans and convertible notes: $1.2 million from affiliates of related parties (FFF-II and Fang Family Fund, LLC), $0.6 million from three other lenders (Fannet Technologies, Inc., Anchor Investment, LLC and BioVanta Investment LLC), and $1.8 million of convertible notes, of which $0.3 million converted into 84,045 shares of common stock in August 2026. The Fannet and Anchor loans were repaid in full as described above. The FFF- II, Fang Family Fund, LLC, and the BioVanta Investment LLC notes bear interest at 0% to 6% and are due between February and September 2027, or earlier upon our receipt of external funding. The FFF II and Fang Family Fund loans become due on payment terms to be determined if we do not receive at least $1.0 million of external funding within two months of the deposit date. The BioVanta loan becomes due in six months from issuance if we do not receive at least $2.0 million of external funding within two months of the deposit date. See notes to our unaudited condensed consolidated financial statements for details.
40
Table of Contents
On November 04, 2026, the Company, through SynCardia Systems, LLC, entered into a development and manufacturing agreement for the Freedom Driver System requiring aggregate development payments of $0.5 million payable upon specified milestones. The initial $0.2 million payment had not been made as of the date of this Quarterly Report. The Company expects to fund these obligations from available cash resources and additional financing, as available.
Cash Flows
The following table shows a summary of our cash flows (in thousands):
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Net cash used in operating activities |
|
$ | (7,148 | ) |
|
$ | (11,296 | ) |
Net cash used in investing activities |
|
$ | (26 | ) |
|
$ | - |
|
Net cash provided by (used in) financing activities |
|
$ | (4,249 | ) |
|
$ | 14,061 |
|
Net cash used in operating activities
Net cash used in operating activities of $7.1 million for the nine months ended September 30, 2026 was primarily attributable to (i) a $15.5 million Net loss, (ii) a $6.4 million non-cash gain from Change in fair value of the Senior secured note and Warrant liability and (iii) $0.1 million increase in government grant receivable; offset by (i) a $10.2 million non-cash Loss on settlement of debt, (ii) $1.5 million net change in working capital, (iii) $1.6 million in Stock-based compensation, (iv) $0.5 million non-cash Loss on the warrant exchange, (v) $0.1 million in depreciation and amortization, (vi) $0.7 million increase in Provision of excess and obsolete inventory, and (vii) $0.3 million in amortization of right-of- use asset.
Net cash used in operating activities of $11.3 million for the nine months ended September 30, 2025, was primarily attributable to a $22.7 million Net loss; and $1.7 million net change in working capital; offset by (i) $11.6 million in Derivative loss and Amortization of discount on debt issued, (ii) $0.6 million increase in Provision for excess and obsolete inventory, (iii) a $0.5 million increase in Stock-based compensation, (iv) $0.1 million depreciation and amortization and (v) a $0.3.million increase in Amortization of right of use assets.
Net cash used in investing activities
Net cash used in investing activities was $0.03 million and $0 million for the nine months ended September 30, 2026 and 2025, respectively.
Net cash provided by (used in) financing activities
Net cash used in financing activities was $4.2 million for the nine months ended September 30, 2026, primarily consisting of (i) repayment of $9.5 million in notes payable and (ii) $0.06 million Repayments of finance lease obligations; (iii) $0.6 million of repayments of convertible note to third party; offset by (i) $0.3 million of Proceeds from loans from related party, net of repayments, (ii) a $0.06 million of Stock option exercise, (iii) $3.1 million of Proceeds from issuance of common stock and warrants, (iv) $0.6 million of proceeds from issuance of short term notes; and (v) $1.8 million of proceeds from issuance of convertible notes to third party.
Net cash provided by financing activities was $14.1 million for the nine months ended September 30, 2025, which primarily consisted of net proceeds of $15.2 million, $2.0 million, $2.2 million, and $2.9 million from the issuance of common stock, convertible notes, stock subscriptions, and related party notes, respectively, offset by $8.2 million in repayments of related party loan notes.
Off-Balance Sheet Arrangements
As of September 30, 2026 and December 31, 2025, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.
41
Table of Contents
Critical Accounting Policies and Estimates
Management’s discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires our management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. We evaluate these judgments, assumptions and estimates for changes that would affect the reported amounts. These estimates are based on management’s historical industry experience and on various other judgments and assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these judgments, assumptions and estimates. A discussion of recent accounting pronouncements and our significant accounting policies, including further discussion of the accounting policies described below, can be found in Note 2 “Summary of Significant Accounting Policies” to our condensed consolidated financial statements included in this quarterly report. None of those policies are deemed to be critical accounting policies nor critical accounting estimates.
China Distribution Agreement
In October 2026, we notified SynCardia Beijing, our exclusive distributor in mainland China, Hong Kong, Macau and Taiwan, that we are terminating our distribution and registration services agreements effective December 15, 2026, and we no longer intend to make the investment described in Note 7. After that date, we will no longer sell through SynCardia Beijing. We are evaluating the effect on our net product sales and results of operations and cannot reasonably estimate it at this time. Continued sales in these territories will depend on our ability to establish alternative distribution and maintain product registrations. See Part II, Item 1A, Risk Factors.
Emerging Growth Company Status
Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act for complying with new or revised accounting standards applicable to public companies. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates for such new or revised standards. We may elect to comply with public company effective dates at any time, and such election would be irrevocable pursuant to Section 107(b) of the JOBS Act.
We are also a “smaller reporting company” as defined in Regulation S-K under the Securities Act and may elect to take advantage of certain of the scaled disclosures available to smaller reporting companies. We may be a smaller reporting company even after we are no longer an “emerging growth company.”
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Accounting Officer, to allow timely decisions regarding required disclosure.
42
Table of Contents
Disclosure Controls and Procedures
As required by Rules 13a-15 and 15d-15 under the Exchange Act, our management, including our Chief Executive Officer and Chief Accounting Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based upon their evaluation, our Chief Executive Officer and Chief Accounting Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective due to the material weaknesses in internal control over financial reporting described below. Thus, there remains a reasonable possibility that a material misstatement of the Company’s interim financial statements will not be prevented or detected on a timely basis. This does not include an evaluation by the Company’s registered public accounting firm regarding the Company’s internal control over financial reporting.
Management’s evaluation was based on the following material weaknesses in our internal control over financial reporting which existed as of September 30, 2026, and which continue to exist:
|
● |
Lack of segregation of duties due to limited accounting personnel. |
|
● |
Lack of a formal review process that includes multiple levels review over financial disclosure and reporting processes. |
Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.
Remediation Plan
Management continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively.
The remediation actions planned include:
|
● |
Retain additional accounting personnel with public company financial reporting, technical accounting, SEC compliance, and strategic financial advisory experience to achieve adequate segregation of duties; |
|
● |
Implement multiple level reviews over financial disclosure and reporting processes; |
Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Accounting Officer, as appropriate, to enable timely decisions regarding required disclosures, and is recorded, processed, summarized, and reported within the time periods specified in the rules and forms promulgated by the SEC. Our management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and there is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For a description of our legal proceedings and contingencies, see Note 7-Commitments and Contingencies, (d) Litigation to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q, which information is incorporated by reference herein.
43
Table of Contents
ITEM 1A. RISK FACTORS
Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in Part I, Item 1A. Risk Factors of our Form 10-K, filed with the SEC on March 30, 2026. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. Except for as set forth below, as of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in Part I, Item 1A. Risk Factors of our Form 10-K, filed with the SEC on March 30, 2026, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
There can be no assurance that we will be able to comply with the continued listing standards of the NYSE.
On May 8, 2026, we received the NYSE Notice from the NYSE indicating we were no longer in compliance with the Section 1003(a)(ii) in the Company Guide since the Company reported stockholders’ equity of $3.8 million as of December 31, 2025, and had net losses in three of its four most recent fiscal years then ended (the "Stockholders' Equity Rule"). The Company timely submitted its Compliance Plan, advising of actions it has taken or will take to regain compliance with Section 1003(a)(ii) of the Guide by November 8, 2027. On July 22, 2026, PMI received a letter from the NYSE American stating that the PMI's Compliance Plan had been accepted. As of September 30, 2026, the Company reported stockholders' equity of $1.3 million. There can be no guarantee that the Company’s Compliance Plan or that the Company will meet requirements of its quarterly reviews and/or regain compliance by the November 8, 2027, deadline.
If the NYSE delists our common stock from trading on its exchange and we are not able to list such securities on another national securities exchange, we expect such securities could be quoted on an over-the-counter market. If this were to occur, we and our stockholders could face significant material adverse consequences including:
|
● |
A limited availability of market quotations for our common stock; |
|
● |
Reduced liquidity for our common stock; |
|
● |
A limited amount of news and analyst coverage; and |
|
● |
A decreased ability to obtain additional financing in the future. |
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS FROM REGISTERED SECURITIES
In July 2026, the Company issued 199,311 shares of Common Stock to a holder of the Senior Secured Note in full settlement of $1.4 million of the outstanding balance of the Senior Secured Note, without payment of additional consideration to the Company. The issuance was made in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.
On August 10, 2026, the Company issued 84,045 shares of Common Stock to the holder of a convertible promissory note upon the holder’s election to convert the full $0.3 million principal amount of the note and related accrued interest, without payment of additional consideration to the Company. The issuance was made in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the quarter ended September 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
44
Table of Contents
ITEM 6. EXHIBITS
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
Exhibit No. |
|
Description |
| 1.1 |
|
Placement Agency Agreement, dated May 5, 2026, by and between the Company and the Placement Agent (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 11, 2026). |
| 3.1 |
|
Certificate of Amendment, dated July 21, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 22, 2026). |
3.2 |
|
Amendment to the Amended and Restated Bylaws of Picard Medical Inc., effective October 7, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 13, 2026). |
| 4.1 |
|
Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 11, 2026). |
| 4.2 |
|
Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed with the SEC on May 11, 2026). |
| 4.3 |
|
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K, filed with the SEC on May 11, 2026). |
| 4.4 |
|
Warrant to Purchase Shares of Common Stock, dated May 5, 2026 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 5, 2026). |
| 4.5 |
|
Convertible Promissory Note, dated as of April 7, 2026, issued by the Company in favor of the Buyer (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 13, 2026). |
4.6 |
|
Form of Unsecured Convertible Note issued by Picard Medical Inc. on September 30, 2026 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 6, 2026). |
4.7 |
|
Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed with the SEC on October 6, 2026). |
| 10.1 |
|
Form of Purchase Agreement, dated May 5, 2026, by and among the Company. and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 11, 2026). |
| 10.2 |
|
Warrant Issuance and Exchange Agreement, dated as of May 5, 2026, by and between Picard Medical, Inc. and the investor signatory thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 5, 2026). |
| 10.3 |
|
Securities Purchase Agreement, dated April 7, 2026, by and between the Company and the Buyer (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 13, 2026). |
10.4 |
|
Form of the Warrant Amendment and Exchange Agreement, dated as of October 20, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 23, 2026). |
31.1 |
|
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 |
|
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1** |
|
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2** |
|
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.INS |
|
Inline XBRL Instance Document |
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB |
|
Inline XBRL Taxonomy Extension Labels Linkbase Document |
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
** |
These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
45
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PICARD MEDICAL, INC. |
|
|
|
|
|
By: |
/s/ Richard Fang |
|
Name: |
Richard Fang |
|
Title: |
Chief Executive Officer and Director |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Quarterly Report has been signed below by the following persons in the capacities and on the dates indicated.
Signature |
|
Position |
|
Date |
|
|
|
|
|
| /s/ Richard Fang |
|
Chief Executive Officer and Director |
|
November 16, 2026 |
| Richard Fang |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Georgina Smith |
|
Chief Accounting Officer |
|
November 16, 2026 |
Georgina Smith |
|
(Chief Accounting Officer and Principal Financial Officer) |
|
|
46